TY - JOUR
T1 - Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis
AU - Bhatia, Neal
AU - Gold, Linda Stein
AU - Kircik, Leon H.
AU - Schreiber, Rhonda
N1 - Publisher Copyright:
© 2019 Journal of Drugs in Dermatology. All rights reserved.
PY - 2019/8
Y1 - 2019/8
N2 - Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations. Objective: To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis. Methods: Two randomized, double-blind, vehicle-controlled clinical studies were conducted in 560 adult subjects with moderate to severe plaque psoriasis. Subjects applied the assigned test article to all psoriatic plaques twice daily for 14 days. The key efficacy measures were the proportion of subjects with “treatment success,” defined as those subjects that achieved a score of 0 (clear) or 1 (almost clear) and at least a two-grade improvement compared to baseline for the Investigator’s Global Assessment (IGA) and for the clinical signs of psoriasis (plaque elevation, scaling, and erythema) as well as pruritus. Safety measurements included adverse events and local skin reactions in the treatment area. Results: HBP-Foam was statistically superior to vehicle in achieving “Treatment Success” in 25.3% and 30.7% vs 3.9% and 7.4% (these P<0.001) subjects in Studies experienced 1 and 2, a respectively. significant reduction Pruritus in scores the Do clinical statistically Not signs improved of Copy psoriasis by (plaque over 30% elevation, in HBP-Foam scaling, treated and erythema). subjects. In In contrast, addition, in similar the vehicle in both groups the HBP-Foam the decrease and vehicle in psoriasis-related treatmentPenalties groups. signs was generally Apply not observed. Safety outcomes were unremarkable and Conclusions: These results demonstrate the safety and effectiveness of HBP-Foam in the treatment of plaque psoriasis. Furthermore, this novel foam formulation has demonstrable for its ease of application over large and/or hairy treatment areas.
AB - Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations. Objective: To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis. Methods: Two randomized, double-blind, vehicle-controlled clinical studies were conducted in 560 adult subjects with moderate to severe plaque psoriasis. Subjects applied the assigned test article to all psoriatic plaques twice daily for 14 days. The key efficacy measures were the proportion of subjects with “treatment success,” defined as those subjects that achieved a score of 0 (clear) or 1 (almost clear) and at least a two-grade improvement compared to baseline for the Investigator’s Global Assessment (IGA) and for the clinical signs of psoriasis (plaque elevation, scaling, and erythema) as well as pruritus. Safety measurements included adverse events and local skin reactions in the treatment area. Results: HBP-Foam was statistically superior to vehicle in achieving “Treatment Success” in 25.3% and 30.7% vs 3.9% and 7.4% (these P<0.001) subjects in Studies experienced 1 and 2, a respectively. significant reduction Pruritus in scores the Do clinical statistically Not signs improved of Copy psoriasis by (plaque over 30% elevation, in HBP-Foam scaling, treated and erythema). subjects. In In contrast, addition, in similar the vehicle in both groups the HBP-Foam the decrease and vehicle in psoriasis-related treatmentPenalties groups. signs was generally Apply not observed. Safety outcomes were unremarkable and Conclusions: These results demonstrate the safety and effectiveness of HBP-Foam in the treatment of plaque psoriasis. Furthermore, this novel foam formulation has demonstrable for its ease of application over large and/or hairy treatment areas.
UR - http://www.scopus.com/inward/record.url?scp=85071558266&partnerID=8YFLogxK
M3 - Article
C2 - 31424709
AN - SCOPUS:85071558266
SN - 1545-9616
VL - 18
SP - 790
EP - 796
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 8
ER -